Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Equity Ratio (2020 - 2025)

Gain Therapeutics has reported Equity Ratio over the past 6 years, most recently at 0.54 for Q3 2025.

  • Quarterly results put Equity Ratio at 0.54 for Q3 2025, down 13.15% from a year ago — trailing twelve months through Sep 2025 was 0.54 (down 13.15% YoY), and the annual figure for FY2024 was 0.61, down 10.43%.
  • Equity Ratio for Q3 2025 was 0.54 at Gain Therapeutics, up from 0.38 in the prior quarter.
  • Over the last five years, Equity Ratio for GANX hit a ceiling of 0.93 in Q1 2021 and a floor of 0.38 in Q2 2025.
  • Median Equity Ratio over the past 5 years was 0.68 (2023), compared with a mean of 0.7.
  • Biggest five-year swings in Equity Ratio: soared 38.3% in 2021 and later crashed 38.78% in 2025.
  • Gain Therapeutics' Equity Ratio stood at 0.89 in 2021, then fell by 12.28% to 0.78 in 2022, then decreased by 13.72% to 0.68 in 2023, then fell by 10.43% to 0.61 in 2024, then fell by 11.03% to 0.54 in 2025.
  • The last three reported values for Equity Ratio were 0.54 (Q3 2025), 0.38 (Q2 2025), and 0.5 (Q1 2025) per Business Quant data.